Timely donor lymphocyte infusion (DLI) following the detection of impending molecular relapse may significantly improve ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Molecular Partners AG announced positive results from a Phase 1/2a trial of its tetraspecific T-cell engager MP0533 for relapsed/refractory acute myeloid leukemia (AML) during the 30th EHA Congress.

– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – – 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior ...

HOUSTON -- Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor. A pooled ...

Uproleselan did not significantly improve overall survival in the intent-to-treat population of relapsed/refractory AML patients. Primary refractory AML patients showed a substantial survival benefit ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...